Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293260 · ClinicalTrials.gov registry record · Phase 3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
A Phase 3 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
NCT07293260 is a Phase 3 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 406 participants.
The verdict
NCT07293260, a Phase 3 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Interventions
- DRUG Placebo
- DRUG Olpasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2028-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07293260
The ClinicalTrials.gov registry entry for NCT07293260 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07293260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07293260 about?
NCT07293260 is a clinical study titled "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial". The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
What is the current status of trial NCT07293260?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2026-03-23. Estimated completion is 2028-06-15.
What interventions are being tested in trial NCT07293260?
The interventions under investigation include: Placebo (DRUG), Olpasiran (DRUG).
Who is sponsoring clinical trial NCT07293260?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.